Rituximab as a maintenance treatment in patients with pemphigus vulgaris: When is the right time for discontinuation?

美罗华 医学 低丙种球蛋白血症 维持疗法 中止 天疱疮 寻常性天疱疮 类风湿性关节炎 内科学 强的松 淋巴瘤 免疫学 重症监护医学 肿瘤科 抗体 化疗
作者
Zeinab Aryanian,Kamran Balighi,Seyed Naser Emadi,Parvaneh Hatami
出处
期刊:Journal of Cosmetic Dermatology [Wiley]
卷期号:23 (2): 406-408
标识
DOI:10.1111/jocd.16030
摘要

Rituximab is a monoclonal anti-CD20 antibody with a promising effect in controlling some immune-mediated disorders including pemphigus vulgaris.1 Due to the relapsing nature of autoimmune disorders, multiple courses of rituximab might be needed to keep patients in remission. On the other hand, long-term use of B-cell depleting agents would be associated with some complications including a higher risk for developing serious infections, hypogammaglobulinemia, and even emerging malignancies.2 The scheduling, safety profile, and optimal dosing for long-term maintenance therapy with rituximab in pemphigus has yet remained to be determined. Hence, we focused on existing data in this regard and tried to summarize the experience of rheumatologists, neurologists, and dermatologists on long-term administration of rituximab to provide a practical guide for clinicians. After an appropriate response to induction therapy with rituximab, some experts prefer to continue a maintenance dose versus re-treatment after relapses. Although re-treatment approach is logically superior due to using lower doses of rituximab, Fowler et al revealed that maintenance therapy in patients with non-Hodgkin lymphoma for up to 2 years was associated with a significantly higher complete response rate at the end of the study versus those merely received re-treatment on relapses. Moreover, 3-year overall survival rates were the same in two groups of patients.3 Longer maintenance therapies were reported by rheumatologists in rheumatoid arthritis and other disorders. Charles et al. conducted a study in 39 centers in France to evaluate the clinical effect of continuing rituximab infusions for an extra 18 months, after completion of a standard 18 months of maintenance treatment among patients with ANCA-associated vasculitis. They found a lower rate of relapse in patients receiving 36 months of treatment.4 Another study on 1246 patients with rheumatoid arthritis with over 5 years of recurrent administration of rituximab failed to show any predisposition to severe or opportunistic infections among patients.5 A cohort study on 107 patients with multiple sclerosis, treatment with a mean duration of 33.2 months did not show an increased risk of adverse events.6 Studies investigating the best protocol for maintenance therapy with rituximab are scarce and there is no consensus on immunologic or clinical criteria enabling clinician to decide about discontinuation of treatment. The suggested items are negative direct immunofluorescence results, persistent complete clinical remission, serum anti–desmoglein 1 and 3 autoantibody levels less than 14 U/mL for at least 1 year, measures of B-cell depletion/reconstitution or markers of disease activity.7 Rituximab-associated B-cell depletion is a dose-dependent effect.8 However, it might not be a precise predictor of disease activity. There are some reports in the literature with evidence of ongoing inflammation despite of B-cell depletion. von Büdingen et al. reported a case of relapsing multiple sclerosis with CNS inflammation and presence of oligoclonal band in CSF even after nearly 7 years of anti-CD20 therapy and B-cell depletion, indicating active antibody synthesis by long-lasting plasma cells in possible ectopic lymphoid aggregates in the meninges. They suggested the oligoclonal band as a useful endpoint for rituximab therapy in patients with multiple sclerosis.9 Barra et al. also reported a subgroup of patients with multiple sclerosis, experiencing clinical relapse despite CD20 counts of zero who has been considered as nonresponders, went to remission with receiving further doses of rituximab.6 Those experts supporting the re-dosing of rituximab based on B-cell return, hypothesized that higher relative percentages of peripheral regulatory B cells at the time of B-cell repopulation after rituximab may be associated with more prolonged remission.10 Another suggested tool for predicting the adverse effects during long-term rituximab treatment is determining the Staphylococcus aureus (S. aureus) nasal carriage status. Besada et al. conducted a study on 29 patients suffering from granulomatosis with polyangiitis who received a cumulative rituximab dose of 9 g for remission induction and maintenance during 49 months and found that persistent S. aureus nasal carriage was not a risk factor for disease relapses, and interestingly, was associated with a lower frequency of chronic infections and higher level of total serum Ig, compared to non-Sa carriers.11 It could be due to the role of S. aureus in preventing colonization of other bacteria which led to a decrease in chronic infections and hence a better tolerance for long-term rituximab treatment in patients with S. aureus nasal carriage. However, it is not clear that this outcome is significant merely in patients with granulomatosis with polyangiitis, a disease with strong predilection for sinus and nasal mucosa, or could be seen in patients with other disorders under treatment with rituximab. Low IgG levels before the initiation of rituximab treatment, the reduced number of T lymphocytes and age ≥ 65, have been shown to be associated with a high risk of severe infection in long-term rituximab therapy.12 In Pendergraft et al. study on 172 patients with ANCA-associated vasculitis treated with long-term rituximab, the only significant predictor of death was achieving remission at an age greater than 80 years.13 Thietart et al. compared the induction and maintenance phase of rituximab therapy in patients with 75 years and older with ANCA-associated vasculitis and revealed an increase in incidence of serious infections and death only in induction, not in the maintenance phase in old patients and concluded that clinicians need to be focused on reducing serious infections during the first months of therapy in older patients.14 Boleto et al. conducted one of the longest longitudinal studies of rituximab treatment in patient with rheumatoid arthritis and followed patients for up to 12 years. They noted that treatment duration as well as rituximab cumulative doses was not as important as low gamma globulin level prior to rituximab therapy as a prognostic factor for predicting the development of hypogammaglobulinemia.15 From dermatologists' point of view, rituximab is a promising option for both first-line and maintenance treatment of pemphigus.16 Joly et al. published a guideline on management of pemphigus and suggested two infusions of 500 mg rituximab on 12 and 18 months after reaching to a complete remission in patients with pemphigus vulgaris.16 There is not enough data in literature regarding infusion of rituximab after this period of time in those in complete remission. It seems that the most important factor to consider additional rituximab cycles is re-rise of anti-desmoglein antibodies in patients with pemphigus.16 Hence, evaluating of anti-desmoglein antibodies level is strongly suggested at least every 6 months. Previous studies showed that taking rituximab as a first-line treatment in pemphigus patients could lead to a considerably lower rate of adverse effects2 and a better clinical efficacy.1 Hence, early prescription of rituximab during the course of disease might reduce the duration of treatment and the cumulative dose of medication needed for the patients.1 Moreover, there are some limited reports of neoplasm development following rituximab therapy which raise some concerns regarding long-term rituximab therapy.17 Although most of studies in this regard did not find any significant impact of rituximab on developing a secondary malignancy in patients with non-Hodgkin lymphoma,18 a study on 1028 patients with follicular lymphoma with a median follow-up time of 6 years found an increased risk of development of secondary hematological malignancies in patients receiving multiple cycles of rituximab and concluded that achievement of as long remission period as possible should be the aim of treatment.19 A recent study showed an elevated BAFF (B-cell activating factor) level in sera of patients with pemphigus after 3 and 6 months of treatment with rituximab and speculated that BAFF might play an important role in repopulation of B cells after rituximab therapy.20 One can infer that prevention of this repopulation by adding an anti-BAFF medication to rituximab could result in a longer and more prompt clinical effect and a reduction in the number of rituximab cycles, needed for patients with pemphigus. According to above mentioned data, finding the optimal timing and duration of therapy as well as correct scheduling, needs further future randomized investigations. The decision to recommend maintenance rituximab therapy should be upon a much more individually tailored approach and considering risks and benefits of long-term treatment, based on clinical, immunological, and prognostic features of each patient. Monitoring of IgG levels before the initiation of rituximab and every 6–12 months during long-term treatment, evaluating of direct immunofluorescence results, serum anti–desmoglein 1 and 3 autoantibody levels, measurement of B-cell depletion/reconstitution, and probably monitoring of BAFF level could be used for addressing an important and challenging issue of determining who is more likely to experience the relapse and hence, benefits from long-term treatment and who is at an increased risk of toxicity and serious infections in case of long-term rituximab treatment. Moreover, it is rational to closely monitor patients receiving more rituximab cycles for secondary malignancies. Hence, we suggest to perform an oncology consultation for patients on long-term rituximab treatment in this regard. This issue should be evaluated in further studies. We received no funding for this project. P.H and K.B gathered the data. Z.A supervised the project. S.E prepared the initial draft. All authors contributed to the preparation of final draft. All authors contributed to the preparation of data and finalization of this article. The authors would like to thank Razi Hospital Clinical Research Development Center and Autoimmune Bullous Diseases Research Center for their technical and editorial assistance. The authors have no conflicts of interest to declare that are relevant to the content of this article. Since this was a review article, there was no need to have patients' consents. The protocol of study was approved by ethics committee of Tehran University of Medical Sciences. The data that support the findings of this study are available from the corresponding author upon reasonable request.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
傻傻的寄翠完成签到,获得积分10
1秒前
pluto应助Chao采纳,获得30
1秒前
Lucas应助CC采纳,获得10
1秒前
耶豆发布了新的文献求助10
1秒前
瓜子发布了新的文献求助20
1秒前
李健的小迷弟应助lanmo采纳,获得10
3秒前
keyanxiaobai发布了新的文献求助10
3秒前
可爱的函函应助LNN采纳,获得10
3秒前
ColinWine发布了新的文献求助10
3秒前
3秒前
4秒前
SciGPT应助武雨寒采纳,获得10
4秒前
6秒前
7秒前
橙子发布了新的文献求助10
8秒前
懒洋洋发布了新的文献求助20
8秒前
orixero应助徐福采纳,获得10
8秒前
小小K发布了新的文献求助10
9秒前
9秒前
10秒前
11秒前
11秒前
yeahsawyou发布了新的文献求助10
11秒前
14秒前
scsc完成签到,获得积分10
14秒前
初夏发SCI发布了新的文献求助10
15秒前
orixero应助澡雪采纳,获得10
15秒前
JamesPei应助小小K采纳,获得10
16秒前
CodeCraft应助glitter采纳,获得30
16秒前
21秒前
Ava应助大白采纳,获得10
21秒前
22秒前
洗刷刷发布了新的文献求助10
22秒前
彭于晏应助jc哥采纳,获得10
22秒前
nlyk完成签到,获得积分10
25秒前
彩色橘子完成签到 ,获得积分10
25秒前
大模型应助huhu采纳,获得10
25秒前
阳光项链发布了新的文献求助10
26秒前
桐桐应助初夏发SCI采纳,获得10
26秒前
Emma完成签到 ,获得积分10
26秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Effective Learning and Mental Wellbeing 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975836
求助须知:如何正确求助?哪些是违规求助? 3520174
关于积分的说明 11201364
捐赠科研通 3256576
什么是DOI,文献DOI怎么找? 1798362
邀请新用户注册赠送积分活动 877539
科研通“疑难数据库(出版商)”最低求助积分说明 806426